Sorafenib-induced erythema multiforme for metastatic renal cell carcinoma.
Kodaira
M
M
Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research.
Takahashi
S
S
Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research. Electronic address: stakahas@jfcr.or.jp.
Takeuchi
K
K
Department of Pathology.
Yuasa
T
T
Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research.
Saotome
T
T
Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research.
Yonese
J
J
Department of Urology, Cancer Institute of Japanese Foundation for Cancer Research, Tokyo, Japan.
Fukui
I
I
Department of Urology, Cancer Institute of Japanese Foundation for Cancer Research, Tokyo, Japan.
Hatake
K
K
Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D004892:Erythema Multiforme / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000473:pathology / Q000556:secondary; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects*; D000077157:Sorafenib; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib